APA

Shouksmith A. E., Gawel J. M., Nawar N., Sina D., Raouf Y. S., Bukhari S., He L., Johns A. E., Manaswiyoungkul P., Olaoye O. O., Cabral A. D., Sedighi A., de Araujo E. D. & Gunning P. T. (2020). Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. : ACS medicinal chemistry letters.

Chicago

Shouksmith Andrew E, Gawel Justyna M, Nawar Nabanita, Sina Diana, Raouf Yasir S, Bukhari Shazreh, He Liying, Johns Alexandra E, Manaswiyoungkul Pimyupa, Olaoye Olasunkanmi O, Cabral Aaron D, Sedighi Abootaleb, de Araujo Elvin D and Gunning Patrick T. 2020. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. : ACS medicinal chemistry letters.

Harvard

Shouksmith A. E., Gawel J. M., Nawar N., Sina D., Raouf Y. S., Bukhari S., He L., Johns A. E., Manaswiyoungkul P., Olaoye O. O., Cabral A. D., Sedighi A., de Araujo E. D. and Gunning P. T. (2020). Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. : ACS medicinal chemistry letters.

MLA

Shouksmith Andrew E, Gawel Justyna M, Nawar Nabanita, Sina Diana, Raouf Yasir S, Bukhari Shazreh, He Liying, Johns Alexandra E, Manaswiyoungkul Pimyupa, Olaoye Olasunkanmi O, Cabral Aaron D, Sedighi Abootaleb, de Araujo Elvin D and Gunning Patrick T. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. : ACS medicinal chemistry letters. 2020.